Talacotuzumab manufacturers
- Talacotuzumab
-
- $993.00
-
2026-07-27
- CAS:1826831-79-1
- Purity: 98.42% (SEC-HPLC)
- Supply Ability: 10g
|
| | Talacotuzumab Basic information |
| Product Name: | Talacotuzumab | | Synonyms: | Talacotuzumab;Research Grade Talacotuzumab (DHD72501);alacotuzumab;CSL 362|||JNJ 56022473;Research Grade Talacotuzumab;Talacotuzumab (anti-IL-3Ra) | | CAS: | 1826831-79-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Talacotuzumab Structure]() |
| | Talacotuzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Talacotuzumab Usage And Synthesis |
| Uses | Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models[1][2][3][4]. | | in vivo | Talacotuzumab (JNJ 56022473; CSL 362; 300 μg; ip; thrice weekly for 5 weeks) results in a significant delay in tumor growth compared with an isotype control in acute myeloid leukaemia mice xenografts[1].
Talacotuzumab (1, 10, 30 mg/kg; s.c.; single injection) has maximal serum concentrations at 48 hours of ~12, 190, and 380 μg/ml at doses of 1, 10, and 30 mg/kg in naive cynomolgus monkeys, respectively[2].
| Animal Model: | Nonobese diabetic/severe combined immunodeficiency mice injected intravenously AML xenograft cells (AML-5)[1] | | Dosage: | 300 μg | | Administration: | IP; thrice weekly for 5 weeks | | Result: | Resulted in a significant delay in tumor growth compared with an isotype control.
|
| | References | [1] S J Busfield, et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014 Nov;28(11):2213-21. DOI:10.1038/leu.2014.128
[2] Shereen Oon, et al. A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosus. JCI Insight. 2016 May 5;1(6):e86131. DOI:10.1172/jci.insight.86131
[3] Erwin M Lee, et al. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. Haematologica. 2015 Jul;100(7):914-26. DOI:10.3324/haematol.2014.113092
[4] L H Xie, et al. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission. Blood Cancer J. 2017 Jun 2;7(6):e567. DOI:10.1038/bcj.2017.52 |
| | Talacotuzumab Preparation Products And Raw materials |
|